# Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

> **NCT02384122** · PHASE3 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 62 (actual)

## Conditions studied

- Angiodysplasia
- Vascular Malformations
- Gastrointestinal Hemorrhage
- Anemia

## Interventions

- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT02384122
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2022-07
- **Final completion:** 2023-05
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02384122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02384122, "Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02384122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*